Abstract
The Food and Drug Administration (FDA) has determined that entacapone, used in the management of Parkinson's disease, does not increase the risk of prostate cancer or death from prostate cancer.The decision was based on an analysis of data from a postmarketing clinical trial conducted by the drug manufacturer and an FDA review of data from the Department of Veterans Affairs.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
